Genelux Corp (GNLX) Stock Price, Quote & News

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and periton...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 267 9889

Website: www.genelux.com

Address:

2625 Townsgate Road, Suite 230, Westlake Village, United States

JD101 Sep. 9 at 2:14 PM

$LIXT $GNLX $VVOS $PBM $TNYA all in on these 5 bios … each one massive potential

0 · Reply

NVDAMillionaire Sep. 9 at 8:41 AM

$GNLX Outstanding article that hits the mark on GNLX's current state. So if you want to refresh your GNLX insights or learn about GNLX from scratch, this is a must read. https://beyondspx.com/quote/GNLX/analysis/genelux-vaccinia-s-vanguard-in-oncology-s-high-stakes-arena-nasdaq-gnlx

0 · Reply

JD101 Sep. 8 at 7:30 PM

$GNLX you can now smell the data

1 · Reply

Biotechnicity Sep. 4 at 6:19 PM

$GNLX ⬅️ she’s a tease

0 · Reply

JD101 Sep. 4 at 5:33 PM

$GNLX 15K shares deep and I buy a little every day … $10+ soon

2 · Reply

JD101 Sep. 4 at 1:30 AM

$GNLX Fireside Chat at H.C. Wainwright Conference: Scheduled for September 9, 2025, Genelux executives will discuss updates and possibly insights into upcoming data.

1 · Reply

Kupper Sep. 3 at 8:00 PM

$GNLX What's up with the daily volatility?

0 · Reply

JD101 Sep. 3 at 9:30 AM

$GNLX added a bunch yesterday

0 · Reply

cllebye Aug. 31 at 3:42 PM

$GNLX This is a straight up cancer vaccine

0 · Reply

JD101 Aug. 30 at 7:17 PM

$GNLX keep buying till the data drop … $10+ incoming

0 · Reply

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Jul 7, 2025, 7:00 AM EDT - 2 months ago

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

May 6, 2025, 4:10 PM EDT - 4 months ago

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Mar 28, 2025, 4:10 PM EDT - 5 months ago

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 25, 2025, 8:31 AM EDT - 6 months ago

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Feb 3, 2025, 6:45 AM EST - 7 months ago

Genelux Corporation Announces New Chief Financial Officer

Dec 13, 2024, 7:01 AM EST - 9 months ago

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Nov 6, 2024, 4:01 PM EST - 10 months ago

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Oct 31, 2024, 10:59 AM EDT - 11 months ago

Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Oct 22, 2024, 4:01 PM EDT - 11 months ago

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Oct 9, 2024, 4:15 PM EDT - 11 months ago

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

May 24, 2024, 8:00 AM EDT - 1 year ago

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

May 23, 2024, 4:01 PM EDT - 1 year ago

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

May 9, 2024, 4:25 PM EDT - 1 year ago

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

$Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer$

Nov 27, 2023, 7:00 AM EST - 1 year ago

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

Nov 14, 2023, 5:50 PM EST - 1 year ago

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Sep 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 30, 2023, 1:56 PM EDT - 2 years ago

Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

Jul 20, 2023, 4:45 PM EDT - 2 years ago

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

Jul 11, 2023, 4:12 AM EDT - 2 years ago

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

Jun 29, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

Jun 22, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

Jun 12, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $18 Million Private Placement

$Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On$

May 25, 2023, 4:01 PM EDT - 2 years ago

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

May 15, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation Announces $33 Million Private Placement

Mar 26, 2023, 10:50 PM EDT - 2 years ago

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

Mar 23, 2023, 7:00 AM EDT - 2 years ago

Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

Jan 26, 2023, 6:40 AM EST - 2 years ago

Genelux IPO prices at bottom of range

Jan 25, 2023, 9:00 PM EST - 2 years ago

Genelux Corporation Announces Pricing of Initial Public Offering

Sep 19, 2022, 1:49 PM EDT - 3 years ago

IPO Update: Genelux Finalizes $16 Million IPO Plan

Sep 19, 2022, 9:08 AM EDT - 3 years ago

Genelux sets IPO terms, as the biotech could be valued at up to $165 millino

JD101 Sep. 9 at 2:14 PM

$LIXT $GNLX $VVOS $PBM $TNYA all in on these 5 bios … each one massive potential

0 · Reply

NVDAMillionaire Sep. 9 at 8:41 AM

0 · Reply

JD101 Sep. 8 at 7:30 PM

$GNLX you can now smell the data

1 · Reply

Biotechnicity Sep. 4 at 6:19 PM

$GNLX ⬅️ she’s a tease

0 · Reply

JD101 Sep. 4 at 5:33 PM

$GNLX 15K shares deep and I buy a little every day … $10+ soon

2 · Reply

JD101 Sep. 4 at 1:30 AM

$GNLX Fireside Chat at H.C. Wainwright Conference: Scheduled for September 9, 2025, Genelux executives will discuss updates and possibly insights into upcoming data.

1 · Reply

Kupper Sep. 3 at 8:00 PM

$GNLX What's up with the daily volatility?

0 · Reply

JD101 Sep. 3 at 9:30 AM

$GNLX added a bunch yesterday

0 · Reply

cllebye Aug. 31 at 3:42 PM

$GNLX This is a straight up cancer vaccine

0 · Reply

JD101 Aug. 30 at 7:17 PM

$GNLX keep buying till the data drop … $10+ incoming

0 · Reply

Kupper Aug. 29 at 7:53 PM

$GNLX the sentiment is bullish but the price action is bullshit.

1 · Reply

JD101 Aug. 27 at 2:53 PM

$GNLX am I 50% of the daily volume 😂

0 · Reply

Biotechnicity Aug. 27 at 2:25 PM

$GNLX One way traffic over the past 3-months heading into catalysts.

1 · Reply

WealthWielder Aug. 27 at 6:40 AM

$GNLX price action looks indecisive, could go either way with volume shift.

1 · Reply

JD101 Aug. 26 at 4:11 PM

$GNLX I buy more everyday

0 · Reply

Kupper Aug. 25 at 9:08 PM

$GNLX What is up with the price action today. Over $4 back down to $3.75.

1 · Reply

JD101 Aug. 25 at 7:55 PM

$GNLX adding

0 · Reply

Biotechnicity Aug. 25 at 3:57 PM

$GNLX 6-months ago this traded over $4.50. At that time results from the Phase-3 trial in PRROC were at least a year away. We’re 10-months removed now and straddling $4.00 with Phase-2 results in recurrent NSCLC expected within 4 months. 🎯 $5.00 prior to P-2 data. Higher on success. The Olvi-Vec Xmas tree.

1 · Reply

JD101 Aug. 25 at 1:49 PM

$GNLX $10 then $30-+

1 · Reply

Biotechnicity Aug. 24 at 3:39 PM

$GNLX You, sir, are carrying the weight of the entire board. Sadly, less than 500 followers of the ticker, so it remains relatively unknown. That will certainly change!

1 · Reply

JD101 Aug. 21 at 3:54 PM

$LIXT $GNLX $VVOS $KURA $PBM all monsters that I have chips in

4 · Reply

JD101 Aug. 20 at 7:30 PM

$GNLX keep adding here daily under $3.50

0 · Reply

Market Cap	134.47M
Revenue (ttm)	10,000.00
Net Income (ttm)	-29.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-298,700.02%
Debt to Equity Ratio	0.00

Volume	74,800
Avg Vol	129,246
Day's Range	N/A - N/A
Shares Out	37.77M
Stochastic %K	67%
Beta	-0.32
Analysts	Strong Sell
Price Target	$17.60